The Protein Brewery is already in the application process for the US and European markets
Novo Growth, the growth equity arm of Novo Holdings, an investment and asset management company, said it has led a €22 Series A investment in The Protein Brewery, an innovative developer of protein-rich, animal-free food ingredients.
The Protein Brewery is already in the application process for the US and European markets, with regulatory approval anticipated in 2021 in the US and 2022 in Europe.
Thomas Grotkjær, Principal at Novo Holdings, stated, “Integrating alternative proteins that successfully deliver on sustainable development goals is essential to feed a growing world population while taking care of the future of our planet and its people. The company is well positioned to enter a €30 billion-plus market for alternative proteins. This investment underscores Novo Holdings’ commitment to supporting companies that translate biotechnological research and innovation into commercial solutions.”
Wim de Laat, founder of The Protein Brewery, commented, “Providing food for a population of ten billion people by 2050 demands alternative scenarios. The financial support and domain expertise of our investors will help us take the next important step and move towards the realization of a pilot plant, demonstrating the process, the properties and benefits of our innovative and nutritious food ingredient. We are delighted that Novo Holdings, one of the world’s preeminent investors in biotechnology, recognises the potential of our technology to transform the food industry.”
Thomas Grotkjær of Novo Holdings will join the Supervisory Board alongside the other Series A investors, Edouard Nuttin of Roquette Ventures and Kim Odhner of Unovis Asset Management, joining Wim de Laat and existing investors.
Based in the Netherlands, The Protein Brewery was founded in January 2020, resulting from a demerger of BioscienZ, an industrial biotechnology company developing new technologies based on microbial fermentation as a core competence. It was founded in 2010 by Wim de Laat, a molecular scientist with over 30 years’ experience in industrial fermentation. The Series A funding will enable The Protein Brewery to continue its R&D activities, cover operational costs as well as scaling up production of its flagship product Fermotein.